4.88
                                            前日終値:
              $5.26
            開ける:
              $5.24
            24時間の取引高:
                6,608
            Relative Volume:
              0.19
            時価総額:
                $38.47M
            収益:
              $2.34M
            当期純損益:
              $-24.85M
            株価収益率:
              -1.4067
            EPS:
                -3.4691
            ネットキャッシュフロー:
                $-23.25M
            1週間 パフォーマンス:
              -7.49%
            1か月 パフォーマンス:
              -21.29%
            6か月 パフォーマンス:
                +17.59%
            1年 パフォーマンス:
              +0.00%
            Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
RADX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS | 
|---|---|---|---|---|---|---|
| 
                         
                          
                                RADX
                            
                             
                        Radiopharm Theranostics Ltd Adr 
                           | 
                    4.88 | 40.92M | 2.34M | -24.85M | -23.25M | -3.4691 | 
| 
                         
                          
                                VRTX
                            
                             
                        Vertex Pharmaceuticals Inc 
                           | 
                    426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 | 
| 
                         
                          
                                REGN
                            
                             
                        Regeneron Pharmaceuticals Inc 
                           | 
                    642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 | 
| 
                         
                          
                                ALNY
                            
                             
                        Alnylam Pharmaceuticals Inc 
                           | 
                    434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 | 
| 
                         
                          
                                ARGX
                            
                             
                        Argen X Se Adr 
                           | 
                    826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 | 
| 
                         
                          
                                INSM
                            
                             
                        Insmed Inc 
                           | 
                    186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 | 
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 | 
|---|---|---|---|
| 2025-03-12 | 開始されました | B. Riley Securities | Buy | 
Radiopharm Theranostics Ltd Adr (RADX) 最新ニュース
Radiopharm Theranostics Limited: Promising Financial and Clinical Outlook Justifies Buy Rating - TipRanks
Radiopharm (ASX:RAD, Nasdaq:RADX) to Showcase Oncology Pipeline at Deutsche Bank ADR Conference - Kalkine Media
Radiopharm Theranostics to Present at Deutsche Bank ADR Virtual Investor Conference - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Perspective Therapeutics (CATX) - The Globe and Mail
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Globe and Mail
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Manila Times
Radiopharm Theranostics Announces November AGM with Key Resolutions - MSN
Radiopharm Theranostics secures A$35 million in private placement - Investing.com India
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Achieve Life Sciences (ACHV) - The Globe and Mail
Radiopharm Theranostics Accelerates RAD202 Clinical Trial Following Positive Safety Review - MSN
MasterCraft Boat Holdings Inc (MCFT): What the Financials Tell Us - fostersleader.com
Is Buying Stock In Radiopharm Theranostics Ltd ADR (RADX) A Good Move Today? - fostersleader.com
Major Brokerage Firms Issue Research Notes on Surgepays Inc (SURG) - fostersleader.com
Radiopharm Theranostics Limited: Strategic Advancements and Financial Stability Support Buy Rating - TipRanks
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Jazz Pharmaceuticals (JAZZ) - The Globe and Mail
Radiopharm Theranostics Hosts Webinar Series on Radiopharmaceutical Therapies - MSN
Radiopharm Theranostics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Radiopharm Theranostics Limited: Promising Clinical Developments and Strategic Growth Potential Drive Buy Rating - TipRanks
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody By Investing.com - Investing.com India
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody - Investing.com
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) By Investing.com - Investing.com India
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) - Investing.com
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board - GlobeNewswire Inc.
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board By Investing.com - Investing.com India
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board - Investing.com
Radiopharm Theranostics (NASDAQ:RADX) Now Covered by Brookline Capital Management - Defense World
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital - Investing.com
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital By Investing.com - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive By Investing.com - Investing.com South Africa
OKYO Pharma (NASDAQ:OKYO) Trading Up 1% – Here’s Why - Defense World
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and COMPASS Pathways (CMPS) - The Globe and Mail
Radiopharm signs supply agreement with Cyclotek for prostate cancer drug - Investing.com
Radiopharm wins FDA fast track for cancer imaging agent By Investing.com - Investing.com South Africa
Radiopharm wins FDA fast track for cancer imaging agent - Investing.com
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
radiopharm theranostics begins patient dosing in new trial - Investing.com
radiopharm theranostics begins patient dosing in new trial By Investing.com - Investing.com India
radiopharm theranostics shares preclinical data on new cancer therapy By Investing.com - Investing.com South Africa
radiopharm theranostics shares preclinical data on new cancer therapy - Investing.com
Radiopharm secures lutetium-177 supply agreement By Investing.com - Investing.com South Africa
Radiopharm Theranostics Secures Lutetium-177 Supply Agreement with ITM - TipRanks
Radiopharm secures lutetium-177 supply agreement - Investing.com
Radiopharm advances RAD204 trial with expedited phase By Investing.com - Investing.com India
Radiopharm advances RAD204 trial with expedited phase - Investing.com
Radiopharm Theranostics Ltd Adr (RADX) 財務データ
収益
当期純利益
現金流量
EPS
                大文字化:
                 
                  | 
                ボリューム (24 時間):